他汀类联合非诺贝特治疗混合型高脂血症和致动脉粥样硬化血脂异常患者的社区应用

目的探讨他汀类药物联合非诺贝特治疗混合型高脂血症患者以及致动脉粥样硬化性血脂异常患者的疗效和安全性,以找出性价比高的治疗方案。方法将300例混合型高脂血症和致动脉粥样硬化血脂异常患者随机分为辛伐他汀组（A组）、阿托伐他汀联合非诺贝特胶囊组（B组）和辛伐他汀联合非诺贝特胶囊组（C组）,各100例。然后将三组患者治疗前后的血脂水平及不良反应发生率进行比较。结果 B组与C组治疗后6周及12周的血脂水平指标均优于A组（均P〈0.05）,但B组与C组的上述指标之间差异无统计学意义,同时三组不良反应发生率比较差异也无统计学意义（均P〉0.05）。结论他汀类联合非诺贝特在治疗混合型高脂血症和致动脉粥样硬化血脂异常患者中效果优于单用他汀类药物,且安全性也较高,但是辛伐他汀联合非诺贝特胶囊的性价比更高。

Community application of statins combined with Fenofibrate in the treatment of patients with mixed hyperlipidemia and atherosclerosis induced by dyslipidemia

Objective To study the efficacy and safety of statins combined with Fenofibrate in the treatment of patients with mixed hyperlipidemia and atherosclerosis induced by dyslipidemia,in order to find the higher cost-performance treatment method.Methods 300 patients with mixed hyperlipidemia and atherosclerosis induced by dyslipidemia were randomly divided into Simvastatin group（group A）,Atorvastatin combined with Fenofibrate Capsules group（group B） and Simvastatin combined with Fenofibrate Capsules group（group C）,with 100 cases in each group.The vascular function situation and serum lipid levels before and after treatment and adverse reaction incidence of three groups were compared.Results The serum lipid levels of group B and group C at 6th and 12th week after treatment were all better than those of group A（all P 〈0.05）,while those indexes of group B and group C had no significant differences,and the adverse reaction incidence of three groups had no significant difference（all P 〉0.05）.Conclusion The effect of statins combined with Fenofibrate in the treatment of patients with mixed hyperlipidemia and atherosclerosis in duced by dyslipidemia is better than that of single statins,and its safety is higher,while the cost-performance of Sim vastatin combined with Fenofibrate is higher.